Optimizing Antiviral Outcomes Through Clinical Pharmacology

Assessment of Needs

Several new antiviral drugs have become available in recent years including therapies for SARS-CoV2 and long-acting agents for HIV prevention and treatment. This webinar will compare and contrast the clinical pharmacology and concentration-effect associations for contemporary antivirals. Modern analytical approaches to define antiviral pharmacokinetic-dynamic relationships will also be discussed.

Learning Objectives

At the end of this webinar, participants will be able to:

• Define key clinical pharmacology concepts for antiviral drugs
• Compare and contrast the clinical pharmacology and concentration-effect associations for contemporary antivirals
• Describe modern analytical approaches to define pharmacokinetic-dynamic relationships

Registration

Who Should Attend

This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.

Individual registration is required in order to receive CME credit or a certificate of participation.

Registration closes on June 21, 2022, 9:00 AM (PT).

Certificates will be available after the completion of the evaluation and claim form.

For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they or their spouses or partners have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA continuing education activity.

The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies information for the presenter and planners/reviewers are below and in the presentation. All relevant financial relationships with ineligible companies have been mitigated.

Presenter

Dr Kiser has no relevant financial relationships with ineligible companies to disclose. (Updated 02/25/22) 

Planner/Reviewer

Planner/Reviewer 1 has no relevant financial relationships with ineligible companies to disclose. (Updated 03/16/22)
Planner/Reviewer 2 has no relevant financial relationships with ineligible companies to disclose. (Updated 03/16/22)